| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |